Univ. Prof. Dr. Asisa Volz

2020

• Trick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise. (pdf, 1,45 MB)
  Kubinski M., Beicht J., Gerlach T., Volz A., Sutter G., Rimmelzwaan G.F.
  Vaccines (Basel). 2020;8(3):E451. Published 2020 Aug 12. doi:10.3390/vaccines8030451

2018

• CD8+ T cells responding to the Middle East respiratory syndrome coronavirus nucleocapsid protein delivered by vaccinia virus MVA in mice. (pdf, 2,035 KB)
  Veit S., Jany S., Fux R., Sutter G., Volz A.
  Viruses 2018, 10(12), 718; doi:103390/v10120718
• Generation of therapeutic antisera for emerging viral infections. (pdf, 1,600 KB)
  Schmidt R., Beltzig L.C., Sawatsky B., Dolnik O., Dietzel E., Krähling V., Volz A., Suter G., Becker S, von Messling V.
  NPJ Vaccines, 2018 Oct 5, 3:42, doi:10.1038/s41541-0018-0082-4, eCollection
• Immunogenic cell death of dendritic cells following modified vaccinia virus Ankara infection enhances CD8+ T cell proliferation. (pdf, 1,750 KB)
  Tappe K.A., Budida R., Stankov M.V., Frenz T., Shah H., Volz A., Sutter G., Kalinke U., Behrens G.M.N.
  Eur. J. Immunol., 48(12), 2042-2054 (2018)
• Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg Infections. (pdf, 1,755 KB)
  Langenmayer M., Lülf-Averhoff A-T, Adam-Neumair S., Sutter G., Volz A.
  Viruses, 10(9), pii: E452 (2018), doi:10.3390/ v10090452
• Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S. (pdf, 1,39 MB)
  Langenmayer M.C., Lülf-Averhoff A.T., Adam-Neumair S., Fux R., Sutter G., Volz A.
  Biologicals, 54, 58-62 (2018)
• E3L and F1L gene functions modulate the protective capacity of modified vaccinia virus Ankara immunization in murine model of human smallpox. (pdf, 1,221 KB)
  Volz A., Jany S., Freudenstein A., Lantermann M., Ludwig H., Sutter G.,
  Viruses, 10(1), 21 (2018)

2017

• Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo. (pdf, 8,35 MB)
  Altenburg A.F., Sandt C.E. van de, Li B.W.S., MacLoughlin R.J., Fouchier R.A.M., Amerongen G. van, Volz A., Hendriks R.W., Swart R.L. de, Sutter G., Rimmelzwaan G.F., Vries R.D. de.
  Sci. Rep., 7(1), Art. Nr. 8580 (2017). doi:10.1038/s41598-017-08719-y
• A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cells. (pdf, 1,89 MB)
  Link E.K., Brandmüller C., Suezer Y., Ameres S., Volz A., Moosmann A., Sutter G., Lehmann M.H.
  Vaccine, 35(38), 5131-5139 (2017)
• Modified Vaccinia virus Ankara: History, value in basic research, and current perspectives for vaccine development. (pdf, 11 MB)
  Volz A., Sutter G.
  Advances in Virus Res., 97,187-243 (2017)

2016

• Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes. (pdf, 843 KB)
  Lülf A.T., Freudenstein A., Marr L., Sutter G., Volz A.
  Virology, 499, 322-330 (2016)
• Increased protein degradation improves influenza Virus nucleoprotein-specific CD8+ T cell activation in vitro but not in C57BL/6 mice. (pdf, 1,83 MB)
  Altenburg A.F., Sandt C.E. van de, Trierum S.E. van, Gruyter H.L. De, Run P.R. van, Fouchier R.A., Roose K., Saelens X., Volz A., Sutter G., Vries R.D. de,
  Rimmelzwaan G.F.
  J. Virol., 90(22), 10209-10219 (2016)
• Low pathogenic avian influenza (H9N2) in chicken: Evaluation of an ancestral H9-MVA vaccine. (pdf, 1,03 MB)
  Ducatez M., Becker J., Freudenstein A., Delverdier M., Delpont M., Sutter G., Guerin J.-L., Volz A.
  Vet. Microbiol., 189, 59-67 (2016)
• Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.
  (pdf, 1,75 MB)
  Volz A., Lim S., Kaserer M., Lülf A., Marr L., Jany S., Deeg C.A., Pijlman G.P.,
  Koraka P., Osterhaus A.D., Martina B.E., Sutter G.
  Vaccine, 34(16), 1915-1926 (2016)
• Myristoylation increases the CD8+ T cell response to a GFP prototype antigen delivered by modified vaccinia virus Ankara. (pdf, 1,05 MB)
  Marr L., Lülf A.T., Freundenstein A., Sutter G., Volz A.
  J. Gen. Virol., 97(4), 934-940 (2016)
• An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. (pdf, 12,3 MB)
  Haagmans B.L., Brand J.M.A. van den, Raj S.V., Volz A., Wohlsein P., Smits S.L., Schipper D., Bestebroer T.M., Okba N., Fux R., Bensaid A., Solanes Foz D.S., Kuiken T., Baumgärtner W., Segales J., Sutter G., Osterhaus A.D.M.E.
  Science, 351(6268), 77-81 (2016)

2015

• Modifiziertes Vacciniavirus Ankara (MVA) - die Entwicklung als Vektorimpfstoff und Einsatzmöglichkeiten in der Veterinärmedizin. (pdf, 1,43 MB)
  Volz A., Fux R., Langenmayer M.C., Sutter G.
  Berl. Münch. Tierärztl. Wochenschr., 128(11/12), 464-472 (2015)
• Protective efficacy of recombinant Modified Vaccinia vurus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. (pdf, 1,84 MB)
  Volz A., Kupke A., Song F., Jany S., Fux R., Shams-Eldin H., Schmidt J., Becker C., Eickmann M., Becker S., Sutter G.
  J. Virol., 89(19), 8651-8656 (2015)

2014

• Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influeza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. (pdf, 276 KB)
  Kreijtz J.H.C.M., Goeijenbier M., Moesker F.M., Dries L. van den, Goeijenbier S., Gruyter H.L.M. De, Lehmann M.H., Mutsert G. de, Vijver D.A.M.C. van de, Volz A., Fouchier R.A.M., Gorp E.C.M. van, Rimmelzwaan G.F., Sutter G., Osterhaus A.D.M.E.
  Lancet Infect. Dis., 14(12), 1196-1207 (2014)

• Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge. (1,71 MB)
  Doel P. van den, Volz A., Roose J.M., Sewbalaksing V.D., Pijlman G.P., Middelkoop I. van, Duiverman V., Wetering E. van de, Sutter G., Osterhaus A.D.M.E.,
  Byron M.E.E.
  PLOS Neglected Tropical Diseases, 8(9), e3101 (2014)
• Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. (pdf, 817 KB)
  Altenburg A.F., Kreijtz J.H.C.M., Vries R.D. de, Song F., Fux R., Rimmelzwaan G.F., Sutter G., Volz A.
  Viruses, 6(7), 2735-2761 (2014)
• Rapit expansion of CD8+ T cells in wildtype and type I interferon receptor deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara. (5,22 MB)
  Volz A., Langenmayer M., Jany S., Kalinke U., Sutter G.
  J. Virol., 88(18), 10946-10957 (2014)

2013

• Middle east respiratory syndrome Coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies.
  (pdf, 155 KB)
  Song F., Fux R., Provacia L.B., Volz A., Eickmann M., Becker S., Osterhaus A.D.M.E., Haagmans B.L., Sutter G.
  J. Virol., 87(21), 11950-11954 (2013)
• Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies.
  (pdf, 269 KB)
  Volz A., Sutter G.
  Vaccine, 31(39), 4235-4240 (2013)

2012

• Easy and efficient protocols for working with recombinant vaccinia virus MVA.
  (online-abstract)
  Kremer M., Volz A., Kreijtz J.H., Fux R., Lehmann M.H., Sutter G.
  Methods Mol. Biol., 890, 59-92 (2012)
• Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox. (pdf, 2,1 MB)
  Kremer M.*, Suezer Y.*, Volz A.*, Frenz T., Majzoub M., Hanschmann K.-M., Lehmann M.H., Kalinke U., Sutter G.
  PLoS Pathogens, 8(3), e1002557 (2012); *equal contribution

2011

• N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection. (pdf, 3,1 MB)
  Gratz M. S., Suezer Y., Kremer M., Volz A., Majzoub M., Hanschmann K.-M., Kalinke U., Schwantes A., Sutter G.
  J. Virol., 85(7), 3557-3569 (2011)